Kailera Therapeutics vs Illumina
Side-by-side comparison of AI visibility scores, market position, and capabilities
Kailera Therapeutics (Hengrui spinout) raised $1B+ and filed a US IPO (Mar 2026); its lead GLP-1/GIP drug showed 18% weight loss in Phase 3, competing with Mounjaro and Zepbound.
About
Kailera Therapeutics is a clinical-stage biopharmaceutical company spun out of Chinese pharma giant Hengrui Pharmaceuticals, focused on developing next-generation obesity and metabolic disease treatments. Founded to advance a promising portfolio of GLP-1 and GIP-based drug candidates into the US market, Kailera brings a differentiated pipeline built on Hengrui's extensive metabolic disease research, adapted and developed for global regulatory standards and patient populations.\n\nKailera's lead asset is a dual GLP-1/GIP receptor agonist targeting obesity and type 2 diabetes, the same mechanism underlying blockbuster drugs like Mounjaro and Zepbound. In Phase 3 clinical trials, the drug demonstrated 18% average weight loss — a result that positions it competitively against existing approved therapies. The company is pursuing US FDA approval through a standard NDA pathway, targeting the massive and rapidly growing market for prescription obesity medications where demand continues to outpace supply.\n\nKailera filed for a US IPO in March 2026, having raised over $1B in private financing to fund its clinical development program. The Phase 3 weight loss data and the scale of the obesity drug market — projected to exceed $100B annually by the late 2020s — give the IPO strong fundamental support. As GLP-1 drugs redefine the treatment of obesity, metabolic disease, and potentially cardiovascular and neurological conditions, Kailera's differentiated asset and substantial clinical progress position it as a credible entrant in one of biopharma's most competitive and lucrative races.
World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing.
About
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Kailera Therapeutics vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.